

Express Mail Label No.: EV058165343US

Date of Deposit: May 20, 2002

PATENT APPLICATION

Attorney Docket No. 17999-004 CON (BURF-4CON)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Anne De Groot

SERIAL NUMBER: 10/044,703

EXAMINER: Not Yet Assigned

FILING DATE: November 09, 2001

ART UNIT: 1645

FOR: Human T Cell Response to MHC-Binding Motif Clusters

U. S. Patent and Trademark Office
Box Sequence, P. O. Box 2327
Arlington, VA 22202

**STATEMENT IN SUPPORT OF COMPUTER READABLE
FORM SUBMISSION UNDER 37 C.F.R. § 1.821(f)**

I hereby state that the content of the paper and computer readable forms of the Sequence Listing originally filed in parent application U.S.S.N. 09/813,333 in accordance with 37 C.F.R. § 1.821(c) and 1.821(e), respectively, and requested to be transferred to the instant case, are the same. No new matter is added.


Respectfully submitted,

Danielle T. Abramson
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Date: May 20, 2002



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/044,703	11/09/2001	Anne De Groot	17999-004 CON (BURF-4 CON

CONFIRMATION NO. 9101

FORMALITIES LETTER



OC00000007796126

MINTZ LEVIN
One Financial Center
Boston, MA 02111

Date Mailed: 04/04/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**


Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



PATENT APPLICATION
Attorney Docket No. 17999-004 CON (BURF-4CON)



30623

PATENT TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Anne De Groot
SERIAL NUMBER: 10/044,703 EXAMINER: Not Yet Assigned
FILING DATE: November 09, 2001 ART UNIT: 1645
FOR: Human T Cell Response to MHC-Binding Motif Clusters

U. S. Patent and Trademark Office
Box Sequence, P. O. Box 2327
Arlington, VA 22202

TRANSMITTAL LETTER

Enclosed herewith are the following for the above-identified non-provisional patent application:

1. Preliminary Amendment and Response to Notice to Comply with Requirements for Sequence Disclosure (2 pgs);
2. Copy of Notice to Comply with Requirements for Sequence Disclosure (2 pages);
3. Computer Readable Form Copy of the Sequence Listing (1 diskette);
4. Paper Copy of the Sequence Listing (17 pages);
5. Statement in Support of Computer Readable Form Submission (1 page); and
6. Return postcard.

The Commissioner is hereby authorized to charge any fee that may be due, or to credit any overpayment, to Deposit Account No. 50-0311 (Reference No. 17999-004 CON (BURF-4CON)). A duplicate copy of this transmittal letter is enclosed.

Respectfully submitted,

Date: May 20, 2002

Christina / Karakakis, Reg. No. 45,899
Ivor R. Elrifi, Reg. No. 39,529
Attorney for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241